ArticleLancet (London, England)2015
40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study.
Article in Lancet (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06642870 (Rare Autoimmune Self-management Programme Development), which is not on this map. Cited by 251 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rare Autoimmune Self-management Programme Development
Who cites it
251 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Burden and distribution of venous thromboembolism across cancer types and stages: a meta-analysis of observational studies.Frontiers in oncology · 2025Pooled it
- Anthropometric factors and the risk of ovarian cancer: A systematic review and meta-analysis.Cancer reports (Hoboken, N.J.) · 2022Pooled it
- The effectiveness of case management for cancer patients: an umbrella review.BMC health services research · 2022Pooled it
- The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: A systematic review and meta-analysis.Cancer medicine · 2021Pooled it
- Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis.United European gastroenterology journal · 2020Pooled it
- Pooled it
- Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis.Targeted oncology · 2018Pooled it
- Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis.BMJ open · 2018Pooled it
- αO-Conotoxin GeXIVA[1,2] Attenuates Paclitaxel-Induced Neurotoxicity by Suppressing Ferroptosis via the Nrf2/SLC7A11/GSH/GPX4 Pathway.Marine drugs · 2026Article
- Disparities in cancer survival by socioeconomic status: findings from a population-based study of 942 241 Australians from 1980 to 2019.Journal of the National Cancer Institute · 2026Article
- A Tale of Two Conditions: 50 Years of Chronic Illness and Cancer From a Nursing Perspective.Journal of advanced nursing · 2026Article
- QT Prolongation and Arrhythmias in Cancer Therapy: A Narrative Review of Mechanistic and Clinical Studies.Cardiovascular toxicology · 2026Review
- Diagnostic Utility of Serum Krebs von den Lungen-6 (KL-6) and Surfactant Protein-D (SP-D) Levels in Hypersensitivity Pneumonitis.La Medicina del lavoro · 2026Article
- Behavior change technique delivery during routine smoking cessation advice in primary care and associations with abstinence.Translational behavioral medicine · 2026Observational
- [Ovarian tissue cryopreservation and transplantation: a review of clinical progress in fertility preservation].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Patients' experiences of managing their rare rheumatic disease.Rheumatology (Oxford, England) · 2025Article
- Partial Splenic Embolization for Portal Hypertension Before Radical Nephrectomy in Renal Cell Carcinoma Patient: A Case Report.IJU case reports · 2025Article
- Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2025Article
- Self-expandable metal vs. plastic stents for preoperative biliary drainage in patients receiving neoadjuvant chemotherapy.Clinical endoscopy · 2025Review
- Factors associated with ICU mortality and long-term outcomes in immunocompromised patients admitted to the intensive care unit for acute respiratory failure.Annals of intensive care · 2025Article
191 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
backgroundAssessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key insight into the overall effectiveness of the health system, alongside trends in incidence and mortality. For this purpose, we aimed to provide a unique measure of cancer survival.
methodsIn this observational study, we analysed trends in survival with population-based data for 7·2 million adults diagnosed with a first, primary, invasive malignancy in England and Wales during 1971-2011 and followed up to the end of 2012. We constructed a survival index for all cancers combined using data from the National Cancer Registry and the Welsh Cancer Intelligence and Surveillance Unit. The index is designed to be independent of changes in the age distribution of patients with cancer and of changes in the proportion of lethal cancers in each sex. We analysed trends in the cancer survival index at 1, 5, and 10 years after diagnosis for the selected periods 1971-72, 1980-81, 1990-91, 2000-01, 2005-06, and 2010-11. We also estimated trends in age-sex-adjusted survival for each cancer. We define the difference in net survival between the oldest (75-99 years) and youngest (15-44 years) patients as the age gap in survival. We evaluated the absolute change (%) in the age gap since 1971.
findingsThe overall index of net survival increased substantially during the 40-year period 1971-2011, both in England and in Wales. For patients diagnosed in 1971-72, the index of net survival was 50% at 1 year after diagnosis. 40 years later, the same value of 50% was predicted at 10 years after diagnosis. The average 10% survival advantage for women persisted throughout this period. Predicted 10-year net survival adjusted for age and sex for patients diagnosed between 2010 and 2011 ranged from 1·1% for pancreatic cancer to 98·2% for testicular cancer. Net survival for the oldest patients (75-99 years) was persistently lower than for the youngest (15-44 years), even after adjustment for the much higher mortality from causes other than cancer in elderly people.
interpretationThese findings support substantial increases in both short-term and long-term net survival from all cancers combined in both England and Wales. The net survival index provides a convenient, single number that summarises the overall patterns of cancer survival in any one population, in each calendar period, for young and old men and women and for a wide range of cancers with very disparate survival. The persistent sex difference is partly due to a more favourable cancer distribution in women than men. The very wide differences in survival for different cancers, and the persistent age gap in survival, suggest the need for renewed efforts to improve cancer outcomes. Future monitoring of the cancer survival index will not be possible unless the current crisis of public concern about sharing of individual data for public health research can be resolved.
fundingCancer Research UK.
Indexed as
Identifiers
25479696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.